DALLAS, December 09, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today ...

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomniaFiling of daridorexant in Taiwan planned ...

Dr. Makoto Sugita, CMO and President of Nxera Pharma Japan, commented: “This new partnership with Holling will enable us to bring daridorexant, a potential best-in-class treatment, to the growing ...